30
Participants
Start Date
May 1, 2022
Primary Completion Date
July 1, 2023
Study Completion Date
July 30, 2027
RC48- ADC
RC48-ADC 2.0 mg/kg D1,Triplizumab 3mg/kg D2，Q2W
Xiangya Hospital of Central South University
OTHER
First Affiliated Hospital Xi'an Jiaotong University
OTHER
Southwest Hospital, China
OTHER
Tongji Hospital
OTHER
Chongqing University Cancer Hospital
OTHER
Hunan Cancer Hospital
OTHER
The First Affiliated Hospital of Air Force Medicial University
OTHER
Tianjin Medical University Cancer Institute and Hospital
OTHER